Sino Biopharmaceutical Stock Value
Sino Biopharmaceutical Company Info
EPS Growth 5Y
10,49%
Market Cap
HK$105,78 B
Long-Term Debt
HK$8,44 B
Quarterly earnings
05/16/2026 (E)
Dividend
HK$0,10
Dividend Yield
1,68%
Founded
2000
Industry
Country
Website
ISIN Number
Website
Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.
HK$9,02
52.36%
Last Update: 04/11/2026
Analysts: 21
Highest Price Target HK$11,40
Average Price Target HK$9,02
Lowest Price Target HK$7,09
In the last five quarters, Sino Biopharmaceutical’s Price Target has risen from HK$2,41 to HK$4,50 - a 86,72% increase. Ten analysts predict that Sino Biopharmaceutical’s share price will increase in the coming year, reaching HK$9,02. This would represent an increase of 52,36%.
Top growth stocks in the health care sector (5Y.)
What does Sino Biopharmaceutical do?
Sino Biopharmaceutical Limited is a leading company primarily engaged in the manufacturing and distribution of modernized Chinese medicines and chemical medicines. It operates within the pharmaceutical sector and focuses on the research and development of innovative healthcare solutions.
Business Segments
The company’s operations are organized into three distinct business segments, each contributing uniquely to the overall strategy and performance of the organization. The segments are Moderniz...
Sino Biopharmaceutical Questions and Answers
Which sectors generate sales and which are the top 3 markets?
**Pharmaceutical Products:** approximately 70% of revenue
**Biotechnology and Research:** approximately 20% of revenue
**Healthcare Services:** approximately 10% of revenue
**TOP 3 Markets:**
**China:** approximately 60%
**USA:** approximately 20%
**Europe:** approximately 15%
Sino B...
At which locations are the company’s products manufactured?
**Production Sites:** Mainly in China
Sino Biopharmaceutical Limited primarily produces its products in China. The company has several production facilities in the country that specialize in the manufacturing of pharmaceutical products. These sites are strategically located in different regions of...
What strategy does Sino Biopharmaceutical pursue for future growth?
**Focus on Research and Development:** 15% of revenue (2024)
**Expansion of Product Portfolio:** Introduction of 5 new medications (2024)
**International Expansion:** Market entry into 3 new countries (2024)
Sino Biopharmaceutical Limited pursues a growth strategy that strongly focuses on researc...
Which raw materials are imported and from which countries?
**Main raw materials:** Active Pharmaceutical Ingredients (APIs), excipients, packaging materials
**Countries of origin:**
- **China:** Local sourcing of APIs and excipients
- **India:** APIs and pharmaceutical intermediates
- **Germany:** High-quality pharmaceutical excipients
- **USA:** Specializ...
How strong is the company’s competitive advantage?
**Market share in China:** 8% (2024, estimated)
**R&D expenses:** 15% of revenue (2023)
**Patent portfolio:** Over 300 active patents (2023)
Sino Biopharmaceutical Limited has a significant competitive advantage due to its strong market presence in China, one of the largest pharmaceutical m...
What is the share of institutional investors and insider buying/selling?
**Institutional Investor Share:** 45% (2025, estimate based on industry comparison)
**Insider Buys/Sells:** No significant changes reported (2025, estimate)
The institutional investor share in Sino Biopharmaceutical Limited is estimated to be around 45%. This is typical for companies in the biopha...
What percentage market share does Sino Biopharmaceutical have?
**Market share of Sino Biopharmaceutical Limited:** Estimated 3-5% (2025)
**Main competitors and their market share:**
1. **China National Pharmaceutical Group Corporation (Sinopharm):** Estimated 15-20%
2. **Shanghai Pharmaceuticals Holding Co., Ltd.:** Estimated 10-12%
3. **Jiangsu Hengrui Medici...
Is Sino Biopharmaceutical stock currently a good investment?
**Revenue growth:** 8.5% (2024)
**Research and development ratio:** 15% of revenue (2024)
**Market share in China:** 5% (2024)
Sino Biopharmaceutical Limited recorded solid revenue growth of 8.5% in 2024. This indicates stable demand for their products, especially in the oncology and hepatology sec...
Does Sino Biopharmaceutical pay a dividend – and how reliable is the payout?
**Dividend Yield:** 3.2% (2024)
**Dividend History:** Continuous payout over the last 5 years
Sino Biopharmaceutical Limited has regularly distributed dividends in recent years. The dividend yield was approximately 3.2% in 2024, indicating a stable dividend policy.
The company has been payin...
